

# Casirivimab/Imdevimab (REGEN-COV<sup>™</sup>) ORDER SHEET

## \*Patient will receive an outpatient appointment. DO NOT SEND PATIENT TO THE HOSPITAL\*

**REGEN-COV**<sup>TM</sup> is authorized by FDA for the emergency use for treatment of individuals with mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization as defined in the EUA.

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_\_ Age: \_\_\_\_\_ Patient Contact Number: \_\_\_\_\_\_

Date of COVID-19 symptom onset (infusion must be within 10 days):

Date of positive COVID-19 test:\_\_\_\_\_

### Does this patient:

- □ Require hospitalization due to COVID-19
- □ Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 for patients that require oxygen at baseline due to underlying non-COVID-19 comorbidity
- □ Have an age less than 18 years old
- □ Weigh less than 40 kg

## \*\*\*If any box is checked, STOP- this patient is not eligible for therapy\*\*\*

Risk factors (please check all that apply)

## ADULTS (age > 18) and have at least one of the below criteria:

- $\Box \quad \text{Are} \geq 65 \text{ years of age}$
- □ Obesity or being overweight (for example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical\_charts.htm)
- □ Chronic kidney disease
- Diabetes
- □ Immunosuppressive disease or currently receiving immunosuppressive treatment
- Pregnancy
- □ Cardiovascular disease OR hypertension
- □ Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- □ Sickle cell disease
- □ Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- □ Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID 19)

Physician Signature: Date/Time:
---------------------------------

Physician Printed Name: \_\_\_\_\_

Fax this request to: (540) 245-7951



Monoclonal Antibody Infusion Clinic 201 Lew Dewitt Blvd, Waynesboro VA 22980 Phone: (540) 245-7040 Fax: (540) 245-7959

# Casirivimab/Imdevimab (REGEN-COV<sup>™</sup>) ORDER SHEET

Patient Name:	Date of Birth:

## For Monoclonal Infusion Clinic Use Only:

#### I attest that I have:

- □ I attest that the patient meets the requirements for treatment as put forth by the Regen-COV<sup>TM</sup> EUA.
- □ Provided the patient or parent/caregiver with the "Fact Sheet for Patients, Parents, and Caregivers".
- □ I have informed the patient or parent/caregiver that this medication is available as an unapproved drug that is authorized for use under an EUA and discussed information consistent with the EUA, as noted:
  - The patient or parent/caregiver has the option to accept or refuse Regen-COV<sup>™</sup>
  - The significant known and potential risks and benefits of Regen-COV<sup>™</sup>, and the extend to which such potential risks and benefits are unknown
  - Information on available alternative treatments and the risks and benefits of those alternative treatments, including clinical trials
  - Patients treated with Regen-COV<sup>™</sup> should continue to self-isolate and use infection control measures according to the CDC guidelines

# If the patient has one (1) or more risk factors for progression to severe COVID-19 and the above attestations are met, proceed with treatment:

- 1. Obtain vitals upon start of infusion and check vitals every 15 minutes while receiving treatment.
- 2. Place peripheral IV and discontinue IV prior to departure.
- 3. Casirivimab 600 mg and Imdevimab 600 mg IV infusion in 0.9% Sodium Chloride 100 mL, infused over 30 min, at a rate of 250 mL/hour, Once.
- 4. Flush line with normal saline after the end of infusion.
- 5. Observe and monitor patient for at least 1 hour following the end of infusion.
- 6. Obtain vitals every 15 minutes x 4 post infusion.
- 7. May discharge if patient has stable vitals similar to the patient's baseline status on arrival.

#### **PRN for Hypersensitivity**

Diphenhydramine 25-50 mg IVP PRN X 1 dose Epinephrine 0.3 mg IM PRN X 1 dose Methylprednisolone 125 mg IVP PRN X 1 dose

PRN for pain/fever above 38° C

Acetaminophen 650 mg PO PRN X 1 dose

Physician Signature:
----------------------

Date/Time:	

Physician Printed Name: \_\_\_\_\_